Key result
Prediabetes was not associated with a significant increase in the primary composite endpoint of major adverse cardiac events at 24 months compared to normoglycemia.
Why the study?
Does prediabetes increase the risk of major adverse cardiac events and mortality in non-diabetic patients undergoing elective PCI with drug-eluting stents?
Cohort (n=674)
No
Does prediabetes increase the risk of major adverse cardiac events and mortality in non-diabetic patients undergoing elective PCI with drug-eluting stents?
Prediabetes (HbA1c 5.7-6.4%) is an independent predictor of 2-year mortality in non-diabetic patients undergoing elective PCI with drug-eluting stents.
Answers are grounded in this paper and cite their sources.
Prediabetes not linked to higher MACE after elective PCI; leaves open a mortality signal requiring prospective validation.
PURPOSE: Prediabetes is an independent risk factor for cardiovascular disease. However, data on the long term adverse clinical outcomes of prediabetic patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) are scarce. MATERIALS AND METHODS: The study population comprised 674 consecutive non-diabetic patients who underwent elective PCI between April 2007 and November 2010. Prediabetes was defined as hemoglobin A1c (HbA1c) of 5.7% to 6.4%. Two-year cumulative clinical outcomes of prediabetic patients (HbA1c of 5.7% to 6.4%, n=242) were compared with those of a normoglycemic group (<5.7%, n=432). RESULTS: Baseline clinical and angiographic characteristics were similar between the two groups, except for higher glucose levels (104.8±51.27 mg/dL vs. 131.0±47.22 mg/dL, p<0.001) on admission in the prediabetes group. There was no significant difference between the two groups in coronary angiographic parameters, except for a higher incidence of diffuse long lesion in the prediabetes group. For prediabetic patients, trends toward higher incidences of binary restenosis (15.6% vs. 9.8 %, p=0.066) and late loss (0.71±0.70 mm vs. 0.59±0.62 mm, p=0.076) were noted. During the 24 months of follow up, the incidence of mortality in prediabetic patients was higher than that in normoglycemic patients (5.5% vs. 1.5%, p=0.007). CONCLUSION: In our study, a higher death rate and a trend toward a higher incidence of restenosis in patients with prediabetes up to 2 years, compared to those in normoglycemic patients, undergoing elective PCI with contemporary DESs.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2018) conducted a cohort in Non-diabetic patients undergoing elective percutaneous coronary intervention (n=674). Prediabetes (HbA1c 5.7% to 6.4%) vs. Normoglycemia (HbA1c <5.7%) was evaluated on Major adverse cardiac events (composite of cardiovascular mortality, myocardial infarction, or target vessel revascularization) at 24 months (OR 1.61, 95% CI 0.96-2.72, p=0.069). Prediabetes was not associated with a significant increase in the primary composite endpoint of major adverse cardiac events at 24 months compared to normoglycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: